By determining CCR6 expression in the inflammatory environment and detecting mutations in BRAF, ALK, and MAP2K1 in the MAPK signaling pathway, we can establish a precise clinical stratification system for LCH treatment. This evidence concerns the gene BRAF and Langerhans cell histiocytosis.